HALAVEN is a prescription medicine used to treat adults with liposarcoma (a type of soft tissue sarcoma) that cannot be treated with surgery or that has spread to other parts of the body. Patients should have previously received an anthracycline-containing anticancer treatment for advanced or metastatic disease. In a clinical trial, HALAVEN was proven to help some patients live longer.
When used alone after a certain type of anticancer treatment, HALAVEN is the first and only chemotherapy that is proven to help some patients with advanced liposarcoma live longer.
In a clinical trial, HALAVEN was compared to dacarbazine, another chemotherapy. Among the 143 patients with advanced liposarcoma in the trial, some patients lived longer and some did not live as long. Patients with advanced liposarcoma who were treated with HALAVEN lived an average of 15.6 months compared with patients treated with the other chemotherapy, who lived an average of 8.4 months. This means that patients who received HALAVEN lived 86% longer than patients who received the other chemotherapy.
HALAVEN was studied in patients with 3 types of advanced liposarcoma intermediate to high tumor grade. This included patients with dedifferentiated, myxoid/round cell, and pleomorphic liposarcoma.
It's a decision that only you and your health care team can make. That decision will depend on a discussion that might include